---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-384380"
form_type: "8-K"
ticker: "ENGN"
cik: "0001980845"
company_name: "enGene Therapeutics Inc."
filed_at: "2026-09-08T11:33:18+00:00"
generated_at: "2026-09-08T11:35:06.810914+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# enGene Q3 2026 net loss $32.5M; cash $266.3M; BLA filing on track for 4Q 2026

## Summary
- Net loss $32.5M ($0.47/share) vs $29.0M ($0.57/share) year ago; cash $266.3M.
- Total opex $34.0M vs $29.9M; R&D down $2.5M, G&A up $6.6M.
- Pivotal Cohort 1 data update, pre-BLA FDA meeting, and BLA initiation all planned for 4Q 2026.
- Surfactant cohort safety run-in cleared; KOL webinar on Oct 15, 2026.
- Michael Heffernan became Chairman in July 2026, succeeding Richard Glickman.

## SEC filing metadata
- accession: 0001193125-26-384380
- form_type: 8-K
- ticker: ENGN
- cik: 0001980845
- company_name: enGene Therapeutics Inc.
- filed_at: 2026-09-08T11:33:18+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1980845/000119312526384380/0001193125-26-384380-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1980845/000119312526384380/engn-20260908.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-384380
- JSON: https://secwatch.observer/filing/0001193125-26-384380.json
- Plain text: https://secwatch.observer/filing/0001193125-26-384380.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.